Literature DB >> 8815853

A randomized study of the efficacy of the PROPATH Program for patients with Parkinson disease.

B S Mercer1.   

Abstract

OBJECTIVES: To assess (1) the effects of the PROPATH Program, a health management program designed for patients with Parkinson disease, on perceived general health and psychological well-being and satisfaction with medical care, (2) utilization of health care resources by patients with Parkinson disease, and (3) physician impressions of the PROPATH Program.
DESIGN: Patients were randomized to receive either the PROPATH Program in addition to usual care or usual medical care only. All patients and their physicians completed periodic questionnaires designed to assess the study variables.
SETTING: Staff model health maintenance organization from June 1992 through June 1993. PATIENTS: Forty-six English-speaking patients diagnosed with Parkinson disease of Hoehn-Yahr stages I through IV.
RESULTS: Enrollment in the PROPATH Program resulted in a statistically significant improvement in patient perception of general health and psychological well-being after 1 year. There was no significant difference in patient satisfaction with medical care or utilization of health care resources. The large majority of physicians did not find the PROPATH Program to be helpful for development of a treatment plan, management of the illness, identification of problems sooner than by usual treatment, or identification of drug side effects.
CONCLUSIONS: The PROPATH Program may play a useful role in assisting patients to deal with the psychological aspect of Parkinson disease by improving perception of general health and psychological well-being. The program had no significant effect on patient satisfaction with medical care or medical resource utilization.

Entities:  

Mesh:

Year:  1996        PMID: 8815853     DOI: 10.1001/archneur.1996.00550090087014

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  6 in total

1.  Minority enrollment in Parkinson's disease clinical trials.

Authors:  Myra G Schneider; Christopher J Swearingen; Lisa M Shulman; Jian Ye; Mona Baumgarten; Barbara C Tilley
Journal:  Parkinsonism Relat Disord       Date:  2008-08-09       Impact factor: 4.891

Review 2.  A review of the health-related quality of life and economic impact of Parkinson's disease.

Authors:  Clare H Dowding; Claire L Shenton; Sam S Salek
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 3.  Health-related quality-of-life measurement in patients with Parkinson's disease.

Authors:  C Jenkinson; R Fitzpatrick; V Peto
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

4.  Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.

Authors:  Cynthia S Palmer; Mark J C Nuijten; Jordana K Schmier; Prasun Subedi; Edward H Snyder
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

5.  Association between patient education and health-related quality of life in patients with Parkinson's disease.

Authors:  T Shimbo; M Goto; T Morimoto; K Hira; M Takemura; K Matsui; A Yoshida; T Fukui
Journal:  Qual Life Res       Date:  2004-02       Impact factor: 4.147

6.  Clinical Impact and Cost-Effectiveness of an Education Program for PD Patients: A Randomized Controlled Trial.

Authors:  Cindy Canivet; Nadège Costa; Fabienne Ory-Magne; Céline Arcari; Christine Mohara; Laure Pourcel; Hélène Derumeaux; Emilie Bérard; Robert Bourrel; Laurent Molinier; Christine Brefel-Courbon
Journal:  PLoS One       Date:  2016-09-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.